Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Regorafenib (BAY 73-4506) mesylate is an orally active multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1/2/3 (IC50=13/4.2/46 nM), PDGFRβ (IC50: 22 nM), Kit (IC50: 7 nM), RET (IC50: 1.5 nM) and Raf-1 (IC50: 2.5 nM). Regorafenib mesylate has potent anti-tumour and anti-angiogenic effects.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | Regorafenib (BAY 73-4506) mesylate is an orally active multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1/2/3 (IC50=13/4.2/46 nM), PDGFRβ (IC50: 22 nM), Kit (IC50: 7 nM), RET (IC50: 1.5 nM) and Raf-1 (IC50: 2.5 nM). Regorafenib mesylate has potent anti-tumour and anti-angiogenic effects. |
Molecular Weight | 578.92 |
Formula | C22H19ClF4N4O6S |
CAS No. | 835621-08-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Regorafenib mesylate 835621-08-4 inhibitor inhibit